Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Nakano, Yasuhiro ^a   Matoba, Tetsuya ^a   Tokutome, Masaki ^a   Funamoto, Daiki ^a   Katsuki, Shunsuke ^a   Ikeda, Gentaro ^a   Nagaoka, Kazuhiro ^a   Ishikita, Ayako ^a   Nakano, Kaku ^a   Koga, Jun Ichiro ^a   Sunagawa, Kenji ^a   Egashira, Kensuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENYL DERIVATIVE; CARDIOTONIC AGENT; DRUG CARRIER; IRBESARTAN; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TETRAZOLE DERIVATIVE;

ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECT; HEART MUSCLE ISCHEMIA; INTRAVENOUS DRUG ADMINISTRATION; MONOCYTE; MOUSE; MYOCARDITIS; REPERFUSION INJURY; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BIPHENYL COMPOUNDS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; LACTIC ACID; MICE; MONOCYTES; MYOCARDIAL ISCHEMIA; MYOCARDITIS; NANOPARTICLES; POLYGLYCOLIC ACID; REPERFUSION INJURY; TETRAZOLES; TREATMENT OUTCOME;

EID: 84978821802     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29601     Document Type: Article

References (58)

1. Go A. S, et al. Heart disease, and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
2. Menees D. S, et al. Door-To-balloon time, and mortality among patients undergoing primary PCI. N. Engl. J. Med. 369, 901-909 (2013).
3. Hausenloy D. J, & Yellon D. M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 123, 92-100 (2013).
4. Marchant D. J, et al. Inflammation in myocardial diseases. Circ. Res. 110, 126-144 (2012).
5. Vander Heide R. S, & Steenbergen C. Cardioprotection, and myocardial reperfusion: pitfalls to clinical application. Circ. Res. 113, 464-477 (2013).
6. Nahrendorf M, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent, and complementary functions. J. Exp. Med. 204, 3037 (2007).
7. Swirski F. K, et al. Identification of splenic reservoir monocytes, and their deployment to inflammatory sites. Science 325, 612-616 (2009).
8. Tsujioka H, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J. Am. Coll. Cardiol. 54, 130-138 (2009).
9. Hayasaki T, et al. CC chemokine receptor-2 deficiency attenuates oxidative stress, and infarct size caused by myocardial ischemiareperfusion in mice. Circ. J. 70, 342 (2006).
10. Liehn E. A, et al. A New Monocyte Chemotactic Protein-1/Chemokine CC Motif Ligand-2 Competitor Limiting Neointima Formation, and Myocardial Ischemia/Reperfusion Injury in Mice. J. Am. Coll. Cardiol. 56, 1847-1857 (2010).
11. Leuschner F, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005-1010 (2011).
12. Schupp M, Janke J, Clasen R, Unger T, & Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferatoractivated receptor-gamma activity. Circulation 109, 2054-2057 (2004).
13. Kohno T, et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression, and macrophage infiltration in post-infarction ventricular remodeling. Circ. J. 72, 1685-1692 (2008).
14. Jugdutt B. I, et al. Aging-related early changes in markers of ventricular, and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker. Circulation 122, 341-351 (2010).
15. Bouhlel M. A, et al. PPAR' Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties. Cell Metabolism 6, 137-143 (2007).
16. Odegaard J. I, et al. Macrophage-specific PPAR' controls alternative activation, and improves insulin resistance. Nature 447, 1116-1120 (2007).
17. Ahmadian M, et al. PPAR' signaling, and metabolism: the good, the bad, and the future. Nat. Med. 19, 557-566 (2013).
18. Armstrong P. W, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297, 43 (2007).
19. Atar D, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J. Am. Coll. Cardiol. 53, 720-729 (2009).
20. Kimura S, et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 53, 877-883 (2009).
21. Nagahama R, et al. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler. Thromb. Vasc. Biol. 32, 2427-2434 (2012).
22. Katsuki S, et al. Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes. Circulation 129, 896-906 (2014).
23. Nagaoka K, et al. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway, and Anti-Inflammation in a Rat Model. PLoS ONE 10 e0132451 (2015).
24. Ikeda G, et al. Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening. Sci. Rep. 6, 20467 (2016).
25. Dauber I. M, et al. Functional coronary microvascular injury evident as increased permeability due to brief ischemia, and reperfusion. Circ. Res. 66, 986-998 (1990).
26. Takahama H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J. Am. Coll. Cardiol. 53, 709-717 (2009).
27. Acharya S, & Sahoo S. K. PLGA nanoparticles containing various anticancer agents, and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 63, 170-183 (2011).
28. Pascual G, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-? . Nature 437 759-763 (2005).
29. Duan S. Z, Usher M. G, & Mortensen R. M. Peroxisome proliferator-Activated receptor-gamma-mediated effects in the vasculature. Circ. Res. 102, 283-294 (2008).
30. Frohlich G. M, Meier P, White S. K, Yellon D. M, & Hausenloy D. J. Myocardial reperfusion injury: looking beyond primary PCI. Eur. Heart J. 34, 1714-1722 (2013).
31. Cung T. T, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N. Engl. J. Med. 373, 1021-1031 (2015).
32. Jung K, et al. Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts. Circ. Res. 112, 891-899 (2013).
33. Chatelain P, et al. Neutrophil accumulation in experimental myocardial infarcts: relation with extent of injury, and effect of reperfusion. Circulation 75, 1083-1090 (1987).
34. Romson J. L, et al. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67, 1016-1023 (1983).
35. Jolly S. R, et al. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am. Heart J. 112, 682-690 (1986).
36. Baxter G. F. The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Res. Cardiol. 97, 268-275 (2002).
37. Daley J. M, Thomay A. A, Connolly M. D, Reichner J. S, & Albina J. E. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83, 64-70 (2008).
38. Leuschner F, et al. Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ. Res. 107, 1364-1373 (2010).
39. Furze R. C, & Rankin S. M. Neutrophil mobilization, and clearance in the bone marrow. Immunology 125, 281-288 (2008).
40. Ziegler-Heitbrock L. Monocyte subsets in man, and other species. Cellular Immunology 289, 135-139 (2014).
41. Pons S, et al. Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure. J. Cardiovasc. Pharmacol. 42, 17-23 (2003).
42. Vasir J. K, & Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59, 718-728 (2007).
43. Danhier F, et al. PLGA-based nanoparticles: An overview of biomedical applications. J. Control Release 161, 505-522 (2012).
44. Kubo M, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 29, 796-801 (2009).
45. Nakashiro S, et al. Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization, and Rupture by Regulating Monocyte/.Macrophage Differentiation in ApoE- /- Mice. Arterioscler. Thromb. Vasc. Biol. 36, 491-500 (2016).
46. Guo D. F, Sun Y. L, Hamet P, & Inagami T. The angiotensin II type 1 receptor, and receptor-Associated proteins. Cell research 11, 165-180 (2001).
47. Zheng Y, Gardner S. E, & Clarke M. C. H. Cell death, damage-Associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 31, 2781-2786 (2011).
48. Jalowy A, Schulz R, Dörge H, Behrends M, & Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin, and prostaglandins in pigs. J. Am. Coll. Cardiol. 32, 1787-1796 (1998).
49. Harada K, Sugaya T, Murakami K, Yazaki Y, & Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling, and improved survival after myocardial infarction. Circulation 100, 2093-2099 (1999).
50. Ito H. No-reflow phenomenon, and prognosis in patients with acute myocardial infarction. Nat. Clin. Pract. Cardiovasc. Med. 3, 499-506 (2006).
51. Schwartz Longacre L, et al. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 124, 1172-1179 (2011).
52. Sugaya T, et al. Angiotensin II type 1a receptor-deficient mice with hypotension, and hyperreninemia. J. Biol. Chem. 270, 18719-18722 (1995).
53. Ishibashi M, et al. Bone Marrow-Derived Monocyte Chemoattractant Protein-1 Receptor CCR2 Is Critical in Angiotensin IIInduced Acceleration of Atherosclerosis, and Aneurysm Formation in Hypercholesterolemic Mice. Arterioscler. Thromb. Vasc. Biol. 24 e174-e178 (2004).
54. Matsui Y, et al. Distinct Roles of Autophagy in the Heart During Ischemia, and Reperfusion: Roles of AMP-Activated Protein Kinase, and Beclin 1 in Mediating Autophagy. Circ. Res. 100, 914-922 (2007).
55. Hsu C. P, et al. Silent Information Regulator 1 Protects the Heart From Ischemia/Reperfusion. Circulation 122, 2170-2182 (2010).
56. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, & Niwa T. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur. J. Pharm. Biopharm. 45, 41-48 (1998).
57. Takagi H, et al. Activation of PKN mediates survival of cardiac myocytes in the heart during ischemia/reperfusion. Circ. Res. 107, 642-649 (2010).
58. Han K. H, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression, and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111, 1439-1447 (2005).